Vitality Watch

Dossier pubmed preclinical 03-sep-2026
Animal model, organoid, or cell-culture result — not yet human

IL-21R blockade reduces inflammation and atherosclerosis in LDL receptor deficient mice.

Key claim: IL-21R blockade with a monoclonal antibody reduces atherosclerotic plaque area and inflammation in LDL-receptor-deficient mice by expanding atheroprotective Tregs, lowering pro-inflammatory monocytes, and impairing age-associated Tfh–B-cell dynamics.

Abstract

BACKGROUND: Interleukin-21 (IL-21) is a pro-inflammatory cytokine involved in the regulation of both innate and adaptive immune responses and has been associated with atherosclerotic cardiovascular disease (ASCVD). However, the exact role of IL-21/IL-21R signaling in atherosclerosis and the therapeutic potential of targeting this axis remain unclear. METHODS AND RESULTS: scRNAseq of human carotid plaques revealed that IL-21R is highly expressed on Tregs, with increased levels in women versus men and in fibrous plaques versus other phenotypes. In line with these findings, we showed that IL-21R blockade using an anti-IL-21R monoclonal antibody in young (20 weeks) Ldlrmice increased Treg frequencies in secondary lymphoid organs (SLOs), accompanied by increased serum IL-10. Moreover, we observed reduced pro-inflammatory monocytes in the aorta and spleen of anti-IL-21R-treated mice. This contributed to a reduction of 38% in atherosclerotic plaque area (p < 0.05) and 61% less macrophage content (p = 0.053) upon IL-21R blockade. Furthermore, scRNAseq analysis of the spleen and aorta of female Ldlrmice demonstrated an age-associated increase in Il21/Il21r expression within Tregs and Tfh cells. Subsequent IL-21R blockade in aged (88 weeks) Ldlrmice with well-established plaques reduced inflammation, as shown by an increase in aortic Tregs, elevated Foxp3 expression in Tregs from SLOs and reduced pro-inflammatory monocytes. Additionally, anti-IL-21R-treated aged mice showed reduced Tfh cells, as well as reduced plasmablasts and plasma cells. CONCLUSIONS: Collectively, we show that IL-21R blockade attenuates plaque initiation, promotes atheroprotective Tregs, inhibits pro-inflammatory monocytes and impairs Tfh-B cell dynamics upon aging, representing a promising novel therapeutic strategy to combat ASCVD.

Why this matters

IL-21R blockade is a concrete preclinical instance where targeting an adaptive-immune aging axis (Tfh–B-cell activity, Treg balance) translates into reduced atherosclerotic plaque in both young and aged hyperlipidemic mice, with human plaque scRNAseq showing the receptor on Tregs. It is one of the first mechanism studies to tie age-associated germinal-center dynamics directly to vascular lesion biology rather than to systemic cytokine tone alone. The gap to any human-outcome claim remains wide — this is mouse plaque data plus a human expression correlate, not a trial.

Source

Link

Briefing card

IL-21R blockade reduces inflammation and atherosclerosis in LDL receptor deficient mice.
Stage: preclinical · pubmed · 03-sep-2026

Applies to researchers tracking anti-inflammatory add-ons to LDL lowering; there is no human IL-21R blockade trial for cardiovascular aging yet.

IL-21R blockade with a monoclonal antibody reduces atherosclerotic plaque area and inflammation in LDL-receptor-deficient mice by expanding atheroprotective Tregs, lowering pro-inflammatory monocytes, and impairing age-associated Tfh–B-cell dynamics.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.atherosclerosis.2026.121899

build build 880 · 2bcef25 · 2026-11-18